检索

标题
作者
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
Samoylenko I., Demidov L., Moiseenko F., Dvorkin M., Demidova S., Protsenko S., Stroyakovskiy D., Kozlov V., Odintsova S., Kirtbaya D., Tantsyrev D., Mochalova A., Orlova R., Mukhametshina G., Fadeeva N., Fomin E., Chapko Y., Tarasova A., Ermakov N., Shemerovskiy A., Vaschenko V., Chistyakov V., Zinkina-Orikhan A., Lin'kova Y., Kryukov F., Sorokina I., Siliutina A.
Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study
Oganesyan L., Zavalishina L., Ognerubov N., Kostalanova I., Orlov A., Poddubnaya I.
Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study
Choynzonov E., Fedenko A., Falaleeva N., Andreeva T., Afanas'ev S., Bakaev Z., Valiev D., Volkov A., Kolomiets L., Krashikhina T., Miller S., Mikhaliuk V., Ogloblin A., Orlova S., Pataliak S., Pokataev I., Popova N., Rebrina O., Safin R., Stradaeva I., Trefilova I., Usol'tseva I., Usynin E., Sharov S., Iukal'chuk D., Iasieva A.
Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas?
Poddubnaya I.
CAR NK-сells for the treatment of hematological malignancies: A review
Gribkova I.
Systemic treatments for metastatic cutaneous melanoma (Russian Translation of Cochrane Plain Language Summary – PLS)
Ziganshin A.
BCD-100 - first russian PD-1 inhibitor
Tyulyandin S., Fedyanin M., Semiglazova T., Moiseenko V., Odintsova S., Alekseev B., Ivanov R., Shustova M.
Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis
Lyadova M., Fedorinov D., Kuzmina E., Antonova T., Sokolskaya V.
The era of immuno-oncology in onco-urology: what have we achieved? The review of the symposium of the alliance between Merck and Pfizer held within the framework of the XXV Russian Oncology Congress. November 9, 2021
Editorial B.
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Ganshina I., Gordeeva O., Manukian M.
Targetnaya terapiya raka pochki
Alekseev B., Shegay P.
News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)
Oganesyan L., Karnaukhov N., Feoktistova P.
The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
Sarzhevskiy V., Melnichenko V., Panshina I., Mochkin N., Bogatyrov V., Borshevetskaya M., Smirnova E., Bannikova A., Samoylova A., Mamedova A., Rukavitsin A., Vasilev S., Bronov O.
The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer
Tabakov D., Zabotina T., Chanturia N., Zakharova E., Vorotnikov I., Selchuk V., Sokolovskiy V., Petrovsky A.
Novye gorizonty immunoterapii nekhodzhkinskikh limfom iz kletok zony mantii
Poddubnaya I.
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
Yudin D., Laktionov K., Laktionova L., Breder V.
Use of nivolumab for colon cancer with Lynch syndrome
Khakimov G., Tryakin A., Khakimova G.
Place of durvalumab in the treatment of biliary tract cancer: A review
Breder V., Ledin E., Chubenko V., Orlova R., Petkau V., Pokataev I.
Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
Reutova E., Laktionov K.
Opportunities for metastatic triple negative breast cancer therapy
Ganshina I., Gordeeva O., Manukyan M.
Clinical case of complications of immunotherapy – encephalitis
Lyadova M., Kuchevskaya O., Kulikova E.
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
Demina E.
Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
Statsenko G., Kurakin V., Plokhotenko I.
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.
Treatment of advanced small cell lung cancer. Clinical case and literature review
Menshikov K., Sultanbaev A., Musin S., Menshikova I., Nasretdinov A., Sultanbaeva N.
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K., Zhukova L.
Creating a story on the pages of a book about diffuse B-large cell lymphoma
Editorial B.
Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma
Ignatova A.
Durvalumab in the treatment of locally advanced non-small cell lung cancer after chemoradiotherapy in a real practice
Sakaeva D., Ruchkin V., Goncharova O., Abbasova R., Mufazalov F.
1 - 29 的 29 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回(例如,隐含AND)
  • 使用OR结合多个检索词,便于查找含有这些检索词的文章,例如education OR research
  • 使用括号来创建更复杂的查询; 例如:archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如: "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如:online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##